{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:02:19Z","timestamp":1790456539846,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"am","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000056","name":"National Institute of Nursing Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017618","name":"National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.06.005","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:32:45Z","timestamp":1751427165000},"page":"929-934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elexacaftor\/tezacaftor\/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4610-4769","authenticated-orcid":false,"given":"Nora C.","family":"Burdis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-0541","authenticated-orcid":false,"given":"Miranda C.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijana","family":"Milinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"McElvaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-6733","authenticated-orcid":false,"given":"Erika D.","family":"Lease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1889-9769","authenticated-orcid":false,"given":"Siddhartha G.","family":"Kapnadak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2059-3291","authenticated-orcid":false,"given":"Brandon L.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2309-368X","authenticated-orcid":false,"given":"Kathleen J.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jcf.2025.06.005_bib0001","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2025.06.005_bib0002","first-page":"1809","volume":"381","author":"Middleton","year":"2019"},{"issue":"10212","key":"10.1016\/j.jcf.2025.06.005_bib0003","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jcf.2025.06.005_bib0004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of Elexacaftor\/Tezacaftor\/Ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.005_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting Elexacaftor-Tezacaftor-Ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.06.005_bib0006","article-title":"Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up","author":"Beswick","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.005_bib0007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: a Clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.06.005_bib0008","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jcf.2025.06.005_bib0009","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"11","key":"10.1016\/j.jcf.2025.06.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15097","article-title":"Cystic fibrosis survival outcomes following second lung transplant: the north American experience","volume":"37","author":"Alshehri","year":"2023","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.jcf.2025.06.005_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000339627","article-title":"Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients","volume":"86","author":"Vital","year":"2013","journal-title":"Respiration"},{"key":"10.1016\/j.jcf.2025.06.005_bib0012","first-page":"1130","article-title":"Body mass index recovery after lung transplant for cystic fibrosis","volume":"19","author":"Pryor","year":"2022"},{"issue":"5","key":"10.1016\/j.jcf.2025.06.005_bib0013","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.06.005_bib0014","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1016\/j.healun.2021.01.1057","article-title":"Elexacaftor\/Ivacaftor\/Tezacaftor in lung transplant recipients: a case series","volume":"40","author":"Potter","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jcf.2025.06.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","volume":"25","author":"Hayes Jr","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"7","key":"10.1016\/j.jcf.2025.06.005_bib0016","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.jcf.2025.06.005_bib0017","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jcf.2025.06.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2025.100210","article-title":"Evaluation of Elexacafor\/Tezacaftor\/Ivacaftor therapy after lung transplantation in cystic fibrosis: the Dutch national KOALA study","volume":"7","author":"van Gemert","year":"2025","journal-title":"JHLT Open"},{"issue":"3","key":"10.1016\/j.jcf.2025.06.005_bib0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the cystic fibrosis foundation patient registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2025.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry","volume":"13","author":"Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.06.005_bib0021","first-page":"6","article-title":"CFTR modulator therapy in patients with cystic fibrosis and an organ transplant","volume":"27","author":"Mitchell","year":"2018","journal-title":"Paediatr Respir Rev"},{"issue":"7","key":"10.1016\/j.jcf.2025.06.005_bib0022","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.healun.2021.04.011","article-title":"Cystic fibrosis foundation consensus statements for the care of cystic fibrosis lung transplant recipients","volume":"40","author":"Shah","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jcf.2025.06.005_bib0023","unstructured":"Registry CFFP. 2022 annual data report. Bethesda, Maryland: \u00a92023 Cystic Fibrosis Foundation."},{"issue":"11","key":"10.1016\/j.jcf.2025.06.005_bib0024","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1513\/AnnalsATS.202001-030OC","article-title":"Impact of socioeconomic position on access to the U.S. Lung transplant waiting list in a matched cystic fibrosis cohort","volume":"17","author":"Lehr","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2025.06.005_bib0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jcf.2015.11.005","article-title":"Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States","volume":"15","author":"Ramos","year":"2016","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932501519X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932501519X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:34:46Z","timestamp":1779953686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932501519X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S156919932501519X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.06.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}